Kimball Electronics acquires Dutch medical CDMO

Kimball Electronics has acquired Helvoet Polymer Technologies, a Netherlands-based medical CDMO with operations in Europe and India, in a transaction valued at €90m before working capital, customary adjustments, and acquisition-related costs.

Helvoet specialises in highly automated micro-moulding and precision injection moulding for microfluidics, diagnostics, and drug-delivery applications. The company operates manufacturing facilities in Tilburg, Netherlands, and Pune, India, and generated around $56m in revenue in calendar 2025, with more than 70% of sales coming from medical customers.

The acquisition expands Kimball’s medical contract manufacturing platform by adding European production capability, access to India, and a customer base that includes established healthcare companies. Kimball expects the transaction to be accretive to fiscal 2027 adjusted earnings and to increase sales in its medical vertical in the low double-digit range.

Helvoet’s leadership team will remain in place, including CEO Eveline Hogenkamp, supporting continuity for customers already working through long development and qualification cycles. Kimball funded the acquisition through cash and available borrowing capacity on existing credit lines.

Medical devices increasingly combine electronics, plastics, fluidics, sensors, embedded software, and sterilisation-compatible assembly. Diagnostics platforms, drug-delivery devices, lab systems, and connected care products rarely fit into a single manufacturing discipline, which gives integrated contract manufacturing a larger role earlier in development.

Regulated device manufacturing also leaves little room for unstable supplier structures. Qualification, documentation, tooling control, process validation, and traceability can make late changes expensive and slow. The pressure to build resilience into medical device manufacturing has therefore moved from procurement preference to design and operational strategy.

Helvoet’s micro-moulding capability adds a specialised physical layer to Kimball’s medical platform. Diagnostic cartridges, microfluidic assemblies, syringes, drug-delivery systems, and lab consumables depend on small channels, seals, interfaces, and tolerances that directly affect measurement accuracy, dose control, contamination risk, and repeatability. Electronics may provide sensing, processing, and connectivity, but the mechanical and fluidic body of the device often determines whether the system can perform reliably.

The acquisition also reflects a wider move toward certified regional capacity. ESCATEC’s ISO 13485 certification at its Lutterworth electronics manufacturing facility showed the same pattern in the UK, with suppliers investing in quality systems that allow medical OEMs to place more complex work into controlled, documented production environments.

Kimball’s enlarged platform now spans electronics manufacturing and precision medical component production more directly. That combination is becoming useful as healthcare OEMs look for partners able to support design transfer, component sourcing, moulding, assembly, documentation, and logistics without fragmenting responsibility across too many suppliers.

The medical device market is also becoming more demanding on geography. European regulation, UKCA requirements, resilience planning, and supply disruption have all increased the value of qualified manufacturing close to end markets. Helvoet’s Dutch and Indian facilities give Kimball more flexibility across mature European programmes and growing Asian manufacturing requirements.

The deal strengthens Kimball’s position in the manufacturing layers where medical electronics meet precision polymer engineering. As devices become smaller, more connected, and more integrated, the boundary between electronic assembly and physical device production is continuing to narrow.